Business Description
Forward Pharma A/S
ISIN : US34986J1051
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 22.17 | |||||
Equity-to-Asset | 0.95 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | -1.16 | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 31.9 | |||||
3-Year EPS without NRI Growth Rate | 29 | |||||
3-Year FCF Growth Rate | 45.8 | |||||
3-Year Book Growth Rate | -5.9 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 15.11 | |||||
9-Day RSI | 27.35 | |||||
14-Day RSI | 30.85 | |||||
6-1 Month Momentum % | -30 | |||||
12-1 Month Momentum % | -53.33 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 18.43 | |||||
Quick Ratio | 18.43 | |||||
Cash Ratio | 18.33 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.1 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -0.82 | |||||
ROA % | -0.8 | |||||
ROIC % | -388.68 | |||||
ROCE % | -3.66 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shiller PE Ratio | 1.55 | |||||
PB Ratio | 0.16 | |||||
Price-to-Tangible-Book | 0.16 | |||||
EV-to-EBIT | 20.64 | |||||
EV-to-EBITDA | 20.64 | |||||
EV-to-FCF | 217.39 | |||||
Price-to-Projected-FCF | 0.01 | |||||
Price-to-Net-Current-Asset-Value | 0.16 | |||||
Price-to-Net-Cash | 0.16 | |||||
Earnings Yield (Greenblatt) % | 4.84 | |||||
FCF Yield % | -2.42 |